Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Highlights Launches, Late-State Pipeline To Distract From Sluggish Earnings

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO Ian Read admitted tax inversion remains an attractive potential deal-driver for now, though he declined to offer much insight into the company’s near-term M&A strategy.

You may also be interested in...



Pfizer’s Dolsten Explains Why The Big Pharma Can Win The Immuno-Oncology Marathon

Pfizer isn’t considered one of the frontrunners in the immuno-oncology race, but R&D President Mikael Dolsten declares the company, with five agents in the clinic in 2015, will be a force in the therapeutic area.

Over The Counter, 25 October 2021: Building A Global Self-Care Movement With GSCF's Heiko Schipper

In this episode, HBW Insight speaks to Heiko Schipper about the Global Self-Care Federation's recently published Self-Care Readiness Index. 

COVID-19 Era Returns From India Biotech, Healthcare Funds Outpace Others

Early COVID-19 therapies including Gilead’s remdesivir, China-plus procurement policies, vaccine partnerships and a dovish stance by the central bank led to returns on India biotech and healthcare funds outperforming global returns. Meanwhile, funding for e-pharmacies and online consulting firms gathered pace.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077819

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel